Lyell Immunopharma, Inc. is a clinical-stage cell therapy company that develops T cell reprogramming technologies for patients with solid tumors. The company focuses on utilizing ex vivo genetic and epigenetic reprogramming technologies to enhance T cell resistance and durability.

Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

COM:LYELL

Lyell Immunopharma, Inc.

Last Close

1.03

21/11 16:59

Market Cap

402.80M

Beta: -

Volume Today

355.10K

Avg: -

market

industry

website

crunchbase

ipo date

peer of

Metrics